文献速递浆细胞疾病

诱导性T细胞共刺激因子(ICOS)与ICOS配体是多发性骨髓瘤微环境中的新参与因子

Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
PubMed 文献 · Br J Haematol · 2021-12-26

本文报告可溶性ICOS(sICOS)和可溶性ICOSL(sICOSL)在多发性骨髓瘤(MM)中较意义未明单克隆丙种球蛋白病和冒烟型MM升高,且与肿瘤负荷标志物相关;sICOS在Durie-Salmon II/III期倾向于高于I期,并作为独立变量与总生存相关。骨髓瘤细胞和正常浆细胞均表达表面ICOS和ICOSL;体外触发ICOSL抑制骨髓瘤细胞系迁移,体内抑制ICOSL+ MOPC-21骨髓瘤细胞生长。作者认为ICOS/ICOSL代表MM的新标志物和治疗靶点。

要点

  • sICOS和sICOSL水平在MM中较MGUS和冒烟型MM升高。
  • sICOS水平在Durie-Salmon II/III期倾向于高于I期,并作为独立变量与总生存相关。
  • ICOSL触发在体外抑制骨髓瘤细胞系迁移,在体内抑制ICOSL+ MOPC-21细胞生长。

核心结论

  • ICOS和ICOSL代表多发性骨髓瘤的新标志物和治疗靶点。

研究设计与样本

  • 检测多发性骨髓瘤、意义未明单克隆丙种球蛋白病和冒烟型多发性骨髓瘤中sICOS与sICOSL水平,并分析其与肿瘤负荷标志物和总生存的关系。
  • 分析骨髓瘤细胞和正常浆细胞表面ICOS与ICOSL的表达。
  • 体外观察ICOSL触发对骨髓瘤细胞系迁移的影响,体内观察对ICOSL+ MOPC-21骨髓瘤细胞生长的影响。

主要发现

  • sICOS和sICOSL水平在多发性骨髓瘤中较意义未明单克隆丙种球蛋白病和冒烟型多发性骨髓瘤升高。
  • sICOS和sICOSL水平与多个肿瘤负荷标志物存在不同程度的关联。
  • sICOS水平在Durie-Salmon II/III期多发性骨髓瘤中倾向于高于I期,并作为独立变量与总生存相关。
  • 表面ICOS和ICOSL在多发性骨髓瘤细胞和正常浆细胞中均有表达,可能调控不同功能阶段。
  • ICOSL触发在体外抑制骨髓瘤细胞系迁移,在体内抑制ICOSL+ MOPC-21骨髓瘤细胞生长。

临床怎么用

  • 作者认为ICOS和ICOSL代表多发性骨髓瘤的新标志物和治疗靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The inducible T-cell co-stimulator (ICOS) is a T-cell receptor that, once bound to ICOS ligand (ICOSL) expressed on several cell types including the B-cell lineage, plays a decisive role in adaptive immunity by regulating the interplay between B and T cells. In addition to its immunomodulatory functions, we have shown that ICOS/ICOSL signalling can inhibit the activity of osteoclasts, unveiling a novel mechanism of lymphocyte-bone cells interactions. ICOS and ICOSL can also be found as soluble forms, namely sICOS and sICOSL. Here we show that: (i) levels of sICOS and sICOSL are increased in multiple myeloma (MM) compared to monoclonal gammopathy of undetermined significance and smouldering MM; (ii) levels of sICOS and sICOSL variably correlate with several markers of tumour burden; and (iii) sICOS levels tend to be higher in Durie-Salmon stage II/III versus stage I MM and correlate with overall survival as an independent variable. Moreover, surface ICOS and ICOSL are expressed in both myeloma cells and normal plasma cells, where they probably regulate different functional stages. Finally, ICOSL triggering inhibits the migration of myeloma cell lines in vitro and the growth of ICOSL+ MOPC-21 myeloma cells in vivo. These results suggest that ICOS and ICOSL represent novel markers and therapeutic targets for MM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Boggio E, Gigliotti CL, Moia R, et al. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment. Br J Haematol. 2021. PMID: 34954822. doi:10.1111/bjh.17968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。